IP Verse

Compositions And Methods For Tcr Reprogramming Using Fusion Proteins - EP3298033

The patent EP3298033 was granted to TCR Therapeutics on Jul 12, 2023. The application was originally filed on May 18, 2016 under application number EP16797244A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3298033

TCR THERAPEUTICS
Application Number
EP16797244A
Filing Date
May 18, 2016
Status
Patent Maintained As Amended
Jun 9, 2023
Grant Date
Jul 12, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JONES DAYMay 4, 2021ADMISSIBLE

Patent Citations (63) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0239400
DESCRIPTIONEP0519596
DESCRIPTIONEP0592106
DESCRIPTIONEP0638119
DESCRIPTIONEP2258720
DESCRIPTIONUS2005042664
DESCRIPTIONUS2005048617
DESCRIPTIONUS2005100543
DESCRIPTIONUS2005175606
DESCRIPTIONUS2006121005
DESCRIPTIONUS2007014794
DESCRIPTIONUS4816567
DESCRIPTIONUS5199942
DESCRIPTIONUS5225539
DESCRIPTIONUS5350674
DESCRIPTIONUS5399346
DESCRIPTIONUS5530101
DESCRIPTIONUS5565332
DESCRIPTIONUS5580859
DESCRIPTIONUS5585089
DESCRIPTIONUS5585362
DESCRIPTIONUS5589466
DESCRIPTIONUS5766886
DESCRIPTIONUS5858358
DESCRIPTIONUS5883223
DESCRIPTIONUS6120766
DESCRIPTIONUS6326193
DESCRIPTIONUS6331415
DESCRIPTIONUS6352694
DESCRIPTIONUS6407213
DESCRIPTIONUS6534055
DESCRIPTIONUS6548640
DESCRIPTIONUS6692964
DESCRIPTIONUS6797514
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7067318
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7232566
DESCRIPTIONWO0129058
DESCRIPTIONWO0196584
DESCRIPTIONWO2006020258
DESCRIPTIONWO2007024715
DESCRIPTIONWO2010052014
DESCRIPTIONWO2012138475
DESCRIPTIONWO2013126712
DESCRIPTIONWO9109967
DESCRIPTIONWO9317105
INTERNATIONAL-SEARCH-REPORTUS2011189141
INTERNATIONAL-SEARCH-REPORTUS2013323247
OPPOSITIONWO2014031687
OPPOSITIONWO2015164745
OPPOSITIONWO2015164759
OPPOSITIONWO2016070061
OPPOSITIONWO9319163
SEARCHEP0638119
SEARCHEP2258720
SEARCHWO2010052014

Non-Patent Literature (NPL) Citations (11) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Emtage el al., (2008) Second-generation anti-carcinoembryonic antigen designer T cells resist activation-induced cell death, proliferate on tumor contact, secrete cytokines, and exhibit superior antitumor activity in vivo: a preclinical evaluation, Cancer Therapy: Preclinical,14:8112-8122-
OPPOSITION- GROSS et al., "Endowing T cells with antibody specificity using chimeric T cell receptors", The FASEB Journal, (19920000), vol. 6, pages 3370 - 3378, XP002137900-
OPPOSITION- MALLABIABARRENA et al., "An endoplasmic reticulum retention signal in the CD3 epsilon chain of the T-cell receptor", Nature, (19920618), vol. 357, pages 593 - 596, XP055955845-
OPPOSITION- NOLAN et al., "Advances in Brief Bypassing Immunization: Optimized Design of "Designer T Cells" against Carcinoembryonic Antigen (CEA)-expressing Tumors, and Lack of Suppression by Soluble CEA 1", Clinical Cancer Research, (19991200), vol. 5, pages 3928 - 3941-
OPPOSITION- NOLAN et al., "Advances in Brief Bypassing Immunization: Optimized Design of "Designer T Cells" against Carcinoembryonic Antigen (CEA)-expressing Tumors, and Lack of Suppression by Soluble CEA 1", Clinical Cancer Research, (19991200), vol. 5, pages 3928 - 3941, XP055638516-
OPPOSITION- Yun C.O., Nolan K.F., Beecham E.J., Reisfeld R.A., Junghans P., "Targeting of T Lymphocytes to Melanoma Cells Through Chimeric Anti-GD3 Immunoglobulin T-Cell Receptors", Neoplasia, (20000900), vol. 2, no. 5, 99, pages 449 - 459-
OPPOSITION- Goverman J; Gomez S M; Segesman K D; Hunkapiller T; Laug W E; Hood L, "Chimeric Immunoglobulin-T Cell Receptor Proteins Form Functional Receptors: Implications for T Cell Receptor Complex Formation and Activation", Cell, (19900323), vol. 60, pages 929 - 939, XP023908129
OPPOSITION- Megan E. Prosser; Christine E. Brown; Andrew F. Shami; Stephen J. Forman; Michael C. Jensen;, "Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor", Molecular Immunology, (20120000), vol. 51, pages 263 - 272, XP028503025
OPPOSITION- Yun C.O., Nolan K.F., Beecham E.J., Reisfeld R.A., Junghans P., "Targeting of T Lymphocytes to Melanoma Cells Through Chimeric Anti-GD3 Immunoglobulin T-Cell Receptors", Neoplasia, (20000900), vol. 2, no. 5, 99, pages 449 - 459, XP055955830
SEARCH- MOSQUERA LUIS A ET AL, "In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, (20050401), vol. 174, no. 7, ISSN 0022-1767, pages 4381 - 4388, XP002504087 [A] 1-15 * the whole document *-
SEARCH- SOMMERMEYER DANIEL ET AL, "Designer T cells by T cell receptor replacement", EUROPEAN JOURNAL OF IMMUNOLOGY NOV 2006,, (20061101), vol. 36, no. 11, doi:10.1002/EJI.200636539, pages 3052 - 3059, XP002550367 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents